Buserelin is a synthetic gonadotropin-releasing hormone (GnRH) agonist that has been used in medicine for more than 30 years. While it belongs to the peptide hormone family, Buserelin is not a “performance peptide” like BPC-157 or CJC-1295. Instead, it plays a critical role in oncology, gynecology, and reproductive medicine. Clinically, Buserelin is prescribed to:→ Suppress […]
Peptides have exploded in popularity for both medical research and performance enhancement, from BPC-157 for tissue healing to CJC-1295 for growth hormone release. But one of the biggest challenges with peptides is that they’re often short-lived in the body. Many are broken down within minutes to hours, requiring frequent injections to maintain effectiveness — a barrier […]
For decades, C-peptide was considered nothing more than a byproduct of insulin production — a fragment split off when the body converts proinsulin into active insulin. Because it didn’t appear to influence blood sugar directly, clinicians largely ignored it. But over the last 20 years, research has flipped that narrative: C-peptide is now recognized as a […]
In the last five years, GLP-1 receptor agonists (GLP-1 RAs) have gone from being niche diabetes drugs to headline-grabbing weight-loss therapies. Medications like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) are not only reshaping how we treat type 2 diabetes, but also redefining the entire conversation around obesity and metabolic health. The impact is enormous:→ More […]
Non-alcoholic fatty liver disease (NAFLD) and obesity are two of the fastest-growing health problems worldwide. In the U.S. alone, more than 100 million adults are estimated to have fatty liver, with many progressing toward non-alcoholic steatohepatitis (NASH), a serious condition that can lead to cirrhosis and liver failure. At the same time, nearly 42% of American […]